These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38321062)

  • 1. Synthesis, docking, MD simulation, ADMET, drug likeness, and DFT studies of novel furo[2,3-b]indol-3a-ol as promising Cyclin-dependent kinase 2 inhibitors.
    Gheidari D; Mehrdad M; Bayat M
    Sci Rep; 2024 Feb; 14(1):3084. PubMed ID: 38321062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cyclin-dependent kinase 2 CDK2: Insights from molecular docking and dynamics simulation - A systematic computational approach to discover novel cancer therapeutics.
    Chagaleti BK; B SK; G V A; Rajagopal R; Alfarhan A; Arockiaraj J; Muthu Kumaradoss K; Karthick Raja Namasivayam S
    Comput Biol Chem; 2024 Oct; 112():108134. PubMed ID: 38964206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel indenopyrrol-4-one derivatives as potent BRDT inhibitors: synthesis, molecular docking, drug-likeness, ADMET, and DFT studies.
    Gheidari D; Mehrdad M; Bayat M
    J Biomol Struct Dyn; 2024 Sep; 42(15):7860-7873. PubMed ID: 37528682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations.
    Azmy EM; Hagras M; Ewida MA; Doghish AS; Gamil Khidr E; El-Husseiny AA; Gomaa MH; Refaat HM; Ismail NSM; Nassar IF; Lashin WH
    Bioorg Chem; 2023 Oct; 139():106729. PubMed ID: 37467621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
    Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
    Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study on MAPK/ERK and CDK2-Cyclin-E signal switch "on and off" in cell proliferation by bis urea derivatives of 1, 4-Diisocyanatobenzene.
    Nagalakshmamma V; Venkataswamy M; Pasala C; Uma Maheswari A; Thyaga Raju K; Nagaraju C; Chalapathi PV
    Bioorg Chem; 2021 Jul; 112():104940. PubMed ID: 33965780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPK
    Gheidari D; Mehrdad M; Hoseini F
    Front Pharmacol; 2024; 15():1360226. PubMed ID: 39021828
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, biological evaluation, and
    Mandour AA; Nassar IF; Abdel Aal MT; Shahin MAE; El-Sayed WA; Hegazy M; Yehia AM; Ismail A; Hagras M; Elkaeed EB; Refaat HM; Ismail NSM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1957-1973. PubMed ID: 35815597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Oxo-dihydropyranopyran derivatives as anti-proliferative agents; synthesis, biological evaluation, molecular docking, MD simulation, DFT, and
    Ranjbar S; Sadeghian P; Khademian S; Emami M; Jahromi ZP; Mirmajidi SH; Zare F; Negahdaripour M; Ghasemi Y; Khoshneviszadeh M
    Heliyon; 2024 May; 10(9):e29850. PubMed ID: 38707385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
    Pasha FA; Neaz MM
    J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
    Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL
    Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.